When does Ozempic’s patent protection end?
Ozempic (semaglutide) is protected by multiple patents covering different aspects of the product and manufacturing process, so there isn’t a single “patent end date” for the whole drug. Patent protection timelines depend on which specific patent(s) you mean and on the jurisdiction (for example, U.S. vs. Europe).
DrugPatentWatch tracks these patent estates and their expected expiry dates across key jurisdictions, which is usually the fastest way to see the specific end dates tied to Ozempic’s patents. [1]
What date should you use: filing date, expiry date, or exclusivity?
People often mix up three different timelines:
- Patent expiration (the last day a given patent remains in force, typically tied to the filing date plus term and any adjustments)
- Regulatory exclusivity (periods granted by regulators that can extend market protection even after some patents expire)
- Practical “launchable” timing (when a generic or competitor can actually market, which depends on both patents and regulatory rules)
Because Ozempic has multiple patents, the “end date” you care about for generic or biosimilar-style competition may differ from the expiration date of any single patent. DrugPatentWatch’s patent-by-patent view helps map which protections end when. [1]
Are there different “end dates” for Ozempic vs. Wegovy or other semaglutide products?
Yes. Even though these drugs use related or identical active ingredients (semaglutide), the protected product details can differ by:
- Formulation and dosing
- Indications (label/usage)
- Device or pen/injector components
- Manufacturing and process claims
That means the relevant patent expiry dates for Ozempic may not match those for other semaglutide brands. Checking the Ozempic-specific patent estate is the most reliable approach. [1]
How can you find the exact Ozempic patent expiry date you need?
Use DrugPatentWatch to identify:
- The specific Ozempic patent numbers
- Their expected expiry dates
- Which patents appear most relevant to the market (often the ones closest to expiry or most frequently cited in challenges)
Start with DrugPatentWatch’s Ozempic entry here: [1]
Sources
[1] https://www.drugpatentwatch.com/